AIMS: Angiotensin II induces cardiac myocyte apoptosis and hypertrophy, which contribute to heart failure, possibly through enhanced oxidative stress. The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan. METHODS AND RESULTS: A 3 week hemin treatment was tested in an angiotensin II-dependent hypertensive rat model and a cellular model of neonatal rat cardiomyocytes stimulated by angiotensin II. Our findings demonstrate that hemin prevented development of intercellular fibrosis, expression of collagen I, and disorganization of intracellular fibres. Oxidative stress and apoptosis evaluated in hypertensive myocardial tissue were decreased by hemin. The reference treatment with the angiotensin II receptor (AT(1)) antagonist (losartan) was less effective than hemin in prevention of fibrosis and oxidative stress, although it was more effective in reducing hypertension. Rac-1 activation and, subsequently, NADPH oxidase activity were further decreased with hemin than with losartan. Hemin enhanced the expression of phosphoinositide 3-kinase (PI3K) p85 regulatory subunit, in contrast to losartan. The PI3K/Akt signalling pathway activation by hemin was related to heme oxygenase-1 activation and an increase in biliverdin reductase, and its inhibition by LY294002 reversed the effects of hemin on collagen I and caspase-3 expression. Finally, hemin increased Akt activation, and concomitantly decreased RhoA and p38 mitogen-activated protein kinase activation. CONCLUSION: We confirmed a positive effect of hemin on oxidative cardiac damage, apoptosis, and fibrosis induced by hypertension by modulating the NADPH oxidase activation through enhanced expression of the PI3K p85 regulatory subunit.
AIMS: Angiotensin II induces cardiac myocyte apoptosis and hypertrophy, which contribute to heart failure, possibly through enhanced oxidative stress. The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan. METHODS AND RESULTS: A 3 week hemin treatment was tested in an angiotensin II-dependent hypertensiverat model and a cellular model of neonatal rat cardiomyocytes stimulated by angiotensin II. Our findings demonstrate that hemin prevented development of intercellular fibrosis, expression of collagen I, and disorganization of intracellular fibres. Oxidative stress and apoptosis evaluated in hypertensive myocardial tissue were decreased by hemin. The reference treatment with the angiotensin II receptor (AT(1)) antagonist (losartan) was less effective than hemin in prevention of fibrosis and oxidative stress, although it was more effective in reducing hypertension. Rac-1 activation and, subsequently, NADPH oxidase activity were further decreased with hemin than with losartan. Hemin enhanced the expression of phosphoinositide 3-kinase (PI3K) p85 regulatory subunit, in contrast to losartan. The PI3K/Akt signalling pathway activation by hemin was related to heme oxygenase-1 activation and an increase in biliverdin reductase, and its inhibition by LY294002 reversed the effects of hemin on collagen I and caspase-3 expression. Finally, hemin increased Akt activation, and concomitantly decreased RhoA and p38 mitogen-activated protein kinase activation. CONCLUSION: We confirmed a positive effect of hemin on oxidative cardiac damage, apoptosis, and fibrosis induced by hypertension by modulating the NADPH oxidase activation through enhanced expression of the PI3K p85 regulatory subunit.
Authors: Maria G Kapetanaki; Oluwabukola T Gbotosho; Deva Sharma; Frances Weidert; Solomon F Ofori-Acquah; Gregory J Kato Journal: Free Radic Biol Med Date: 2019-08-10 Impact factor: 7.376
Authors: Yiyao Jiang; Xu Zhang; Ting Wei; Xianjie Qi; Isah Amir Abba; Nana Zhang; Yao Chen; Ran Wang; Chao Shi Journal: Front Cardiovasc Med Date: 2022-07-01
Authors: Marina Bayeva; Arineh Khechaduri; Rongxue Wu; Michael A Burke; J Andrew Wasserstrom; Neha Singh; Marc Liesa; Orian S Shirihai; Nathaniel B Langer; Barry H Paw; Hossein Ardehali Journal: Circ Res Date: 2013-05-29 Impact factor: 17.367
Authors: Bianca P Campagnaro; Clarissa L Tonini; Luciano M Doche; Breno V Nogueira; Elisardo C Vasquez; Silvana S Meyrelles Journal: DNA Cell Biol Date: 2013-06-20 Impact factor: 3.311
Authors: Mohammad T Elnakish; Mohamed D H Hassona; Mazin A Alhaj; Leni Moldovan; Paul M L Janssen; Mahmood Khan; Hamdy H Hassanain Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Beverly Giam; Po-Yin Chu; Sanjaya Kuruppu; A Ian Smith; Duncan Horlock; Helen Kiriazis; Xiao-Jun Du; David M Kaye; Niwanthi W Rajapakse Journal: Physiol Rep Date: 2016-04-13